Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.34 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.34 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2938113 | 0.92 | CYP2A6 (0.41) | ALDH1A1CYP2A6CYP1A2CYP3A4CYP11B2 | |
| SCHEMBL31336211 | 0.80 | ALDH1A1 (0.40) | ALDH1A1CYP2A6CYP1A2CYP3A4CHRNB2 | |
| SCHEMBL14983534 | 0.77 | — | — | |
| SCHEMBL14983472 | 0.77 | CYP1A2 (0.32) | CYP1A2CYP2C19LMNAMAPT | |
| SCHEMBL2732528 | 0.76 | CYP2A6 (0.46) | ALDH1A1CYP2A6CYP1A2CYP3A4CYP11B2 | |
| SCHEMBL1136933 | 0.76 | LPL (0.33) | — | |
| SCHEMBL20312452 | 0.76 | — | — | |
| SCHEMBL4078174 | 0.76 | MAPT (0.36) | ALDH1A1CYP2A6CYP1A2CYP3A4CHRNB2 | |
| SCHEMBL13136869 | 0.74 | — | — | |
| SCHEMBL3686725 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022093717-A1 | BORON-CONTAINING CHEMICALS AS CATHODE ADDITIVES, SI ANODE ADDITIVES, ELECTROLYTE ADDITIVES OR SEPARATOR MODIFIERS FOR LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2022-05-05 | — | — | WO | claimed |
| CN-116685327-A | Orphan nuclear receptor modulators for the treatment of pancreatitis, glioblastoma, sarcopenia and stroke | 埃默里大学 | 2023-09-01 | — | — | CN | disclosed |
| WO-2022093717-A1 | BORON-CONTAINING CHEMICALS AS CATHODE ADDITIVES, SI ANODE ADDITIVES, ELECTROLYTE ADDITIVES OR SEPARATOR MODIFIERS FOR LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20220131148-A1 | BORON-CONTAINING CHEMICALS AS CATHODE ADDITIVES, SI ANODE ADDITIVES, ELECTROLYTE ADDITIVES OR SEPARATOR MODIFIERS FOR LI-ION BATTERIES | ENEVATE CORPORATION | 2022-04-28 | — | — | US | disclosed |
| US-20200388885-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH LIPO2F2 SALT-CONTAINING ELECTROLYTE FORMULATIONS | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| US-10654834-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-10504732-B2 | Impurity diffusion agent composition and method for manufacturing semiconductor substrate | TOKYO OHKA KOGYO CO, LTD. (JP) | 2019-12-10 | — | — | US | disclosed |
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | Venenum Biodesign, LLC (US) | 2019-10-31 | — | — | US | disclosed |
| US-20180182624-A1 | IMPURITY DIFFUSION AGENT COMPOSITION AND METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2018-06-28 | — | — | US | disclosed |
| US-20180182624-A1 | IMPURITY DIFFUSION AGENT COMPOSITION AND METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2018-06-28 | — | — | US | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
| EP-1173176-A1 | UTILIZATION OF POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS IN THE PRODUCTION OF MEDICAMENTS FOR PROPHYLAXIS OR TREATMENT OF OBESITY | Aventis Pharma Deutschland GmbH (DE) | 2002-01-23 | — | — | EP | disclosed |
| EP-1157015-A1 | POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENT CONTAINING SAID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2001-11-28 | — | — | EP | disclosed |
| WO-2001070753-A1 | SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-09-27 | — | — | WO | disclosed |
| US-6251922-B1 | TREATMENT OF OBESITY AND DIABETES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-06-26 | — | — | US | disclosed |
| EP-1098891-A1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2001-05-16 | — | — | EP | disclosed |
| US-6159996-A | Polycyclic thiazolidin-2-ylidene amines, process for their preparation, and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-12-12 | — | — | US | disclosed |
| WO-2000051602-A1 | UTILIZATION OF POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS IN THE PRODUCTION OF MEDICAMENTS FOR PROPHYLAXIS OR TREATMENT OF OBESITY | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000051995-A1 | POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENT CONTAINING SAID COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000004006-A1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | GPR119, FFAR1, FFAR3 | ALDH1A1 3170/4885CYP2A6 2012/4885CYP1A2 1439/4885 |
| US-20180182624-A1 | IMPURITY DIFFUSION AGENT COMPOSITION AND METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE | SLC43A1, SAMHD1, SNRPD2 | ALDH1A1 2704/4885CYP2A6 2803/4885CYP1A2 1408/4885 |
| US-10654834-B2 | Non-systemic TGR5 agonists | GPR119, SSTR5, FFAR3 | ALDH1A1 3118/4885CYP2A6 2031/4885CYP1A2 1241/4885 |
| US-10504732-B2 | Impurity diffusion agent composition and method for manufacturing semiconductor substrate | SLC43A1, SAMHD1, SNRPD2 | ALDH1A1 2704/4885CYP2A6 2803/4885CYP1A2 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.